MedTrace Logo

The Real Life Topical Field Treatment of Actinic Keratosis Study

NCT02362152 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1168

Last updated 2019-12-13

No results posted yet for this study

Summary

This non-interventional, multinational study of topical field treatment of actinic keratosis (AK) aims to collect real-life experience with ingenol mebutate as well as one or two other topical field therapies commonly used in the individual country. Physicians will report baseline characteristics, while the main study focus will be on patient reported outcomes 3-4 weeks after treatment completion (treatment satisfaction, adherence, resource utilization and Health Related Quality of Life.

Dermatology centres in Denmark, Norway, Sweden, the Netherlands, the United Kingdom and Canada will participate.

Conditions

  • Actinic Keratosis

Interventions

DRUG

Ingenol mebutate

Topical field treatment as prescribed by dermatologist

DRUG

5-fluorouracil

Topical field treatment as prescribed by dermatologist

DRUG

Imiquimod

Topical field treatment as prescribed by dermatologist

DRUG

Diclofenac

Topical field treatment as prescribed by dermatologist

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Study Director Study Director · LEO Pharma

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02362152 on ClinicalTrials.gov